{"version":"1.0","type":"rich","provider_name":"Acast","provider_url":"https://acast.com","height":250,"width":700,"html":"<iframe src=\"https://embed.acast.com/$/622b8f5080a3a00013890f23/6aac8d4cfca3d5c77b209b7b?\" frameBorder=\"0\" width=\"700\" height=\"250\"></iframe>","title":"Examining physician payments tied to GLP-1 drugs","description":"<p>A Washington Post investigation found that Eli Lilly and Novo Nordisk paid more than $270 million to physicians and other prescribers between 2018 and 2025. On <em>The Gist Healthcare Podcast</em>, <em>Washington Post</em> data reporter <a href=\"https://www.washingtonpost.com/people/lydia-sidhom/\" rel=\"noopener noreferrer\" target=\"_blank\">Lydia Sidhom</a> discusses how the companies’ outreach has expanded across the medical community and what the federal data can and cannot tell us about those payments.&nbsp;</p><p>&nbsp;</p><p>Further reading: <a href=\"https://www.washingtonpost.com/health/2026/09/09/financial-force-helping-drive-americas-craze-glp-1-weight-loss-drugs/\" rel=\"noopener noreferrer\" target=\"_blank\">The largely hidden force helping drive America’s craze for weight-loss drugs</a> (Washington Post)&nbsp;</p>","author_name":"Gist Healthcare Daily"}